Antitumor vaccines: Is it possible to prevent a tumor?

Cancer Immunology, Immunotherapy

Volumn 51, Issue 8, 2002, Pages 409-416

  Lollini, Pier Luigi ^a   Forni, Guido ^b  

^a UNIVERSITY OF BOLOGNA   (Italy)

^b UNIVERSITY OF TURIN   (Italy)

Author keywords

Breast carcinoma; Cancer prevention; HER 2 neu; Immunity; Vaccine

Indexed keywords

CANCER ANTIBODY; GENE PRODUCT; TUMOR ANTIGEN;

AUTOIMMUNITY; BREAST CARCINOMA; CANCER; CANCER INHIBITION; CANCER PREVENTION; CANCER RISK; CARCINOGENESIS; DISEASE MODEL; HEALTH STATUS; IMMUNE RESPONSE; IMMUNOLOGICAL PARAMETERS; MOUSE STRAIN; NONHUMAN; ONCOGENE; ONCOLOGY; PREDICTION; PRIORITY JOURNAL; PROPHYLAXIS; REVIEW; RISK ASSESSMENT; TRANSGENIC MOUSE; TREATMENT OUTCOME; TUMOR IMMUNOLOGY;

ANIMALS; ANTICARCINOGENIC AGENTS; ANTIGENS, NEOPLASM; BREAST NEOPLASMS; CANCER VACCINES; HUMANS; IMMUNIZATION; MICE; MICE, TRANSGENIC; MODELS, BIOLOGICAL; RECEPTOR, ERBB-2; RISK;

EID: 0036047820     PISSN: 03407004     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00262-002-0293-3     Document Type: Review

References (51)

1. Vaccines and vaccination
2. Oncogenic kinase signalling
3. Antitumor vaccination: Where we stand
4. Ability of systemic interleukin-12 to hamper progressive stages of mammary carcinogenesis in HER2/neu transgenic mice
5. Antigenic tumor cell variants obtained with mutagens
6. Tumor antigens recognized by T cells
7. Genetic instability and Darwinian selection in tumours
8. Modeling prostate cancer in the mouse
9. Protective and curative potential of vaccination with IL-2 gene-transfected cells from a spontaneous mouse mammary adenocarcinoma
10. Nerve inflammation halts trial for Alzheimer's drug
11. The Mom1AKR intestinal tumor resistance region consists of Pla2g2a and a locus distal to D4Mit64
12. Human tumour antigens recognized by T cells: New perspectives for anti-cancer vaccines?
13. Noninvasive radioisotopic assessment of pulmonary vascular protein leak. Experimental studies and potential clinical applications
14. Analysis of mammary carcinoma onset and progression in HER-2/neu oncogene transgenic mice reveals a lobular origin
15. Gene transfer as cancer therapy
16. Down-modulation of an oncogene protein product and reversion of the transformed phenotype by monoclonal antibodies
17. Understanding mathematical models for breast cancer risk assessment and counseling
18. Where have all the T cells gone? Mechanisms of immune evasion by tumors
19. Prophylactic cancer vaccines
20. Immune recognition of tumor cells in vivo. I. Role of H-2 gene products in T lymphocyte activation against minor histocompatibility antigens displayed by adenocarcinoma cells
21. Immunoprevention of cancer: Is the time ripe?
22. Vaccination with Her-2/neu DNA or protein subunits protects against growth of a Her-2/neu-expressing murine tumor
23. MHC antigens and tumor escape from immune surveillance
24. How tumors escape immune destruction and what we can do about it
25. Combination immunotherapy of primary prostate cancer in a transgenic mouse model using CTLA-4 blockade
26. The advent of the "unpatients"
27. Demonstration of resistance against methylcholanthrene-induced sarcomas in the primary autochthonous host
28. An epistatic interaction controls the latency of a transgene-induced mammary tumor
29. Specific and nonspecific immunity in the prevention of spontaneous tumours
30. Down regulation of major histocompatibility complex class I expression in mammary carcinoma of HER-2/neu transgenic mice
31. Single-step induction of mammary adenocarcinoma in transgenic mice bearing the activated c-neu oncogene
32. Cytokines, tumour-cell death and immunogenicity: A question of choice
33. Cytokine gene therapy: Hopes and pitfalls
34. Combined allogeneic tumor cell vaccination and systemic interleukin-12 prevents mammary carcinogenesis in HER-2/neu transgenic mice
35. p185(neu) protein is required for tumor and anchorage-independent growth, not for cell proliferation of transgenic mammary carcinoma
36. Antigenic modulation. Loss of TL antigen from cells exposed to TL antibody. Study of the phenomenon in vitro
37. Combined vaccination with major histocompatibility class I and interleukin-2 gene-transduced melanoma cells synergizes the cure of postsurgical established lung metastases
38. HER-2/neu is a tumor rejection target in tolerized HER-2/neu transgenic mice
39. The collaboration of both humoral and cellular HER-2/neu-targeted immune responses is required for the complete eradication of HER-2/neu-expressing tumors
40. Progress in human tumour immunology and immunotherapy
41. DNA vaccination against rat her-2/Neu p185 more effectively inhibits carcinogenesis than transplantable carcinomas in transgenic BALB/c mice
42. Insertion of the DNA for the 163-171 peptide of IL-1 beta enables a DNA vaccine encoding p185(neu) to inhibit mammary carcinogenesis in Her-2/neu transgenic BALB/c mice
43. Enhanced growth of primary tumors in cancer-prone mice after immunization against the mutant region of an inherited oncoprotein
44. Stroma is critical for preventing or permitting immunological destruction of antigenic cancer cells
45. Three different vaccines based on the 140-amino acid MUC1 peptide with seven tandemly repeated tumor-specific epitopes elicit distinct immune effector mechanisms in wild-type versus MUC1-transgenic mice with different potential for tumor rejection
46. Linkage disequilibrium pattern in the L-myc gene in Italian and Japanese non-small-cell lung-cancer patients
47. An inbred colony of oncogene transgenic mice: Diversity of tumours and potential as a therapeutic model
48. Protective immunity against human carcinoembryonic antigen (CEA) induced by an oral DNA vaccine in CEA-transgenic mice
49. Suppression of proliferative response and lymphokine release during the progression of a spontaneous tumor
50. Eradication of established murine tumors using a novel cell-free vaccine: Dendritic cell-derived exosomes